| Study period | |||||
---|---|---|---|---|---|---|
Enrolment | Baseline | Treatment phase | Follow-up phase | |||
Timepoint | − 1 week | 0 week | 4 weeks | 8 weeks | 12 weeks | 24 weeks |
Enrolment | Â | Â | Â | Â | Â | Â |
 Eligibility screen | × |  |  |  |  |  |
 Informed consent | × |  |  |  |  |  |
 Medical history | × |  |  |  |  |  |
 Merger disease | × |  |  |  |  |  |
 Randomization |  | × |  |  |  |  |
Interventions | Â | Â | Â | Â | Â | Â |
 Treatment group |  | × | × | × |  |  |
 Control group |  | × | × | × |  |  |
Assessments | Â | Â | Â | Â | Â | Â |
 MMSE |  | × | × | × | × | × |
 MOCA |  | × | × | × | × | × |
 BI |  | × | × | × | × | × |
 Safety evaluation |  | × |  | × |  |  |
 Adverse events |  | × | × | × | × | × |